# US 2026/0083785 A1 · Uses of bifidobacterium longum transitional microorganism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083785 A1
- Document ID: US20260083785A1
- Status: Published application
- Kind: A1
- Application number: 19/112,879
- Filed: 2023-09-27
- Published: 2026-03-26
- Earliest claimed: 2022-09-27
- Assignees: Societe des Produits Nestle S.A.
- Applicants: SociéTé Des Produits Nestlé S.A.
- Inventors: Cheong Kwet Choy (William) KWONG CHUNG; Jean-Baptiste CAVIN; Claire Laurence Lucie Marie BOULANGE; Eleonora CIARLO
- Web page: https://patentgrep.com/patent/US20260083785A1

## CPC

- A61K 35/745: Bifidobacteria
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a Bifidobacterium longum transitional microorganism for use in preventing and/or reducing the risk of an infection in an infant or young child.

## Claims

### Claim 1

A method of preventing and/or reducing a risk of an infection in an infant or young child, the method comprising administering a Bifidobacterium Longum transitional microorganism to the infant or young child.

### Claim 2

A method of preventing and/or reducing a risk of an infection in an infant or young child, the method comprising administering a prebiotic to the infant or young child; wherein the prebiotic is a glycan substrate or a human milk oligosaccharide (HMO).

### Claim 3 (depends on 1)

The method according to claim 1, wherein the Bifidobacterium Longum transitional microorganism is used administered in combination with a prebiotic selected from the group consisting of a glycan substrate, a human milk oligosaccharide (HMO) and a mixture thereof.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the prebiotic is administered in combination with a Bifidobacterium Longum transitional microorganism.

### Claim 5

A method of preventing and/or reducing the risk of an infection in an infant or young child, the method comprising administering a combination of a Bifidobacterium longum transitional microorganism and a prebiotic to the infant or young child; wherein the prebiotic is selected from the group consisting of glycan substrate, a human milk oligosaccharide (HMO) and a mixture thereof.

### Claim 6 (depends on 5)

The method of claim 5 wherein the prebiotic is a glycan substrate selected from the group recited in any of Tables 1 to 3.

### Claim 7 (depends on 5)

The method of claim 5, wherein the prebiotic is an HMO selected from the group consisting of 2′-FL, 3-FL, di-FL, 3′-SL, 6′-SL, LNT, LNnT, and any combination thereof.

### Claim 8 (depends on 5)

The method of claim 5, wherein the HMO is 3-FL.

### Claim 9 (depends on 5)

The method of claim 5, wherein the Bifidobacterium longum transitional microorganism is: (i) capable of metabolizing the HMO(s) and/or the glycan substrate(s); (ii) preferentially utilizes 3′-fucosyllactose (3-FL) over 2′-fucosyllactose (2′-FL); (iii) is capable of metabolizing a glycan substrate recited in any of Tables 1 to 3; and/or (iv) encodes one or more CAZymes recited in Table 1.

### Claim 10 (depends on 5)

The method of claim 5, wherein the Bifidobacterium longum transitional microorganism has an Average Nucleotide Identity (ANI) of at least 98% with at least one Bifidobacterium longum strain selected from the group consisting of CNCM I-5683, CNCM I-5684, CNCM I-5685, CNCM I-5686, CNCM I-5687, CMCC-P0001 (ATCC BAA-2753), and any combination thereof.

### Claim 11 (depends on 5)

The method of claim 5, wherein the Bifidobacterium longum transitional microorganism and/or the prebiotic: (i) increases levels of IL-6 in the infant or young child; (ii) increases levels of short-chain fatty acids (SCFA) in the infant or young child; and/or (iii) modulates permeability of the gut epithelial barrier.

### Claim 12 (depends on 5)

The method of claim 5, wherein the infection is a viral, bacterial or fungal infection.

### Claim 13 (depends on 5)

The method of claim 5, wherein the infection is an airway infection.

### Claim 14 (depends on 5)

The method of claim 5, wherein the infection is a viral airway infection selected from the group consisting of influenza virus, respiratory syncytial virus, rhinovirus, parainfluenza viruses, metapneumovirus, coronavirus, adenovirus, and bocavirus.

### Claim 15 (depends on 5)

The method of claim 5, wherein the Bifidobacterium longum transitional microorganism further encodes one or more CAZymes selected from Table 2 and 3.

### Claim 16 (depends on 5)

The method of claim 5, wherein the combination of the Bifidobacterium longum transitional microorganism and the prebiotic increases levels of acetate, butyrate and/or propionate in the infant or young child.

### Claim 17 (depends on 5)

The method of claim 5, wherein the combination of the Bifidobacterium longum transitional microorganism and the prebiotic decreases permeability of the gut epithelial barrier in the infant or young child.
